Cargando…

Physical Inactivity in Pulmonary Sarcoidosis

PURPOSE: Reduced physical activity in many chronic diseases is consistently associated with increased morbidity. Little is known about physical activity in sarcoidosis. The aim of this study was to objectively assess physical activity in patients with pulmonary sarcoidosis and investigate its relati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cho, Peter S. P., Vasudevan, Sharmila, Maddocks, Matthew, Spinou, Arietta, Chamberlain Mitchell, Sarah, Wood, Claire, Jolley, Caroline J., Birring, Surinder S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2019
Materias:	Interstitial Lung Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520325/ https://www.ncbi.nlm.nih.gov/pubmed/30888492 http://dx.doi.org/10.1007/s00408-019-00215-6

Ejemplares similares

Repository corticotropin for Chronic Pulmonary Sarcoidosis
por: Baughman, Robert P., et al.
Publicado: (2017)

CASPA (CArdiac Sarcoidosis in PApworth) improving the diagnosis of cardiac involvement in patients with pulmonary sarcoidosis: protocol for a prospective observational cohort study
por: Quijano-Campos, Juan Carlos, et al.
Publicado: (2020)

First patient-centred set of outcomes for pulmonary sarcoidosis: a multicentre initiative
por: Kampstra, Nynke A, et al.
Publicado: (2019)

The King’s Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference
por: Sinha, Aish, et al.
Publicado: (2019)

The Burden of Sarcoidosis Symptoms from a Patient Perspective
por: Voortman, M., et al.
Publicado: (2019)

Psychological burden associated with worse clinical outcomes in sarcoidosis
por: Sharp, Michelle, et al.
Publicado: (2019)

Ranking Self-reported Gastrointestinal Side Effects of Pharmacotherapy in Sarcoidosis
por: Drent, M., et al.
Publicado: (2020)

ILD-specific health-related quality of life in systemic sclerosis-associated ILD compared with IPF
por: Durheim, Michael T, et al.
Publicado: (2020)

Yield of EBUS-TBNA for the diagnosis of sarcoidosis: impact of operator and cytopathologist experience
por: Navasakulpong, Asma, et al.
Publicado: (2016)

Sarcoidosis in the UK: insights from British Thoracic Society registry data
por: Thillai, Muhunthan, et al.
Publicado: (2019)

Needs, Perceptions and Education in Sarcoidosis: A Live Interactive Survey of Patients and Partners
por: Moor, C. C., et al.
Publicado: (2018)

Rationale and design of the SARCoidosis Outcomes in all respiratory Viral Infectious Diseases (SARCOVID) Study
por: Strykowski, Rachel, et al.
Publicado: (2022)

Sarcoidosis and Work Participation: The Need to Develop a Disease-Specific Core Set for Assessment of Work Ability
por: Hendriks, C. M. R., et al.
Publicado: (2019)

Effects of infliximab on lung and circulating natural killer cells, CD56+ T cells and B cells in sarcoidosis
por: Kullberg, Susanna, et al.
Publicado: (2021)

Feasibility of investigating methylphenidate for the treatment of sarcoidosis-associated fatigue (the FaST-MP study): a double-blind, parallel-arm randomised feasibility trial
por: Atkins, Christopher, et al.
Publicado: (2021)

Combined pulmonary fibrosis and emphysema: effect of pulmonary rehabilitation in comparison with chronic obstructive pulmonary disease
por: Tomioka, Hiromi, et al.
Publicado: (2016)

Quantification of pulmonary perfusion in idiopathic pulmonary fibrosis with first pass dynamic contrast-enhanced perfusion MRI
por: Weatherley, Nicholas D, et al.
Publicado: (2021)

Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry
por: Wuyts, Wim A, et al.
Publicado: (2018)

Pneumothorax in Patients with Pulmonary Langerhans Cell Histiocytosis
por: Radzikowska, E., et al.
Publicado: (2018)

Clinicoserological features of antisynthetase syndrome (ASyS)-associated interstitial lung disease presenting to respiratory services: comparison with idiopathic pulmonary fibrosis and ASyS diagnosed in rheumatology services
por: Barratt, Shaney L, et al.
Publicado: (2021)

Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis
por: Hajari Case, Amy, et al.
Publicado: (2017)

Metabolic heterogeneity of idiopathic pulmonary fibrosis: a metabolomic study
por: Zhao, Yidan D, et al.
Publicado: (2017)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry
por: Snyder, Laurie D, et al.
Publicado: (2020)

Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis
por: Kreuter, Michael, et al.
Publicado: (2017)

Neutrophil lymphocyte ratio as an indicator for disease progression in Idiopathic Pulmonary Fibrosis
por: Achaiah, Andrew, et al.
Publicado: (2022)

Cluster analysis of transcriptomic datasets to identify endotypes of idiopathic pulmonary fibrosis
por: Kraven, Luke M, et al.
Publicado: (2023)

Topological data analysis identifies molecular phenotypes of idiopathic pulmonary fibrosis
por: Shapanis, Andrew, et al.
Publicado: (2023)

A qualitative study of informal caregivers’ perspectives on the effects of idiopathic pulmonary fibrosis
por: Belkin, Amanda, et al.
Publicado: (2014)

Rationale for and design of the Idiopathic Pulmonary Fibrosis–PRospective Outcomes (IPF-PRO) registry
por: O'Brien, Emily C, et al.
Publicado: (2016)

Gene correlation network analysis to identify regulatory factors in idiopathic pulmonary fibrosis
por: McDonough, John E, et al.
Publicado: (2019)

In-Hospital Mortality in Patients with Idiopathic Pulmonary Fibrosis: A US Cohort Study
por: Durheim, Michael T., et al.
Publicado: (2019)

Central lung gene expression associates with myofibroblast features in idiopathic pulmonary fibrosis
por: Huang, Yong, et al.
Publicado: (2023)

Sequencing of idiopathic pulmonary fibrosis-related genes reveals independent single gene associations
por: Coghlan, Meghan A, et al.
Publicado: (2014)

Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis
por: Dutta, Prosenjit, et al.
Publicado: (2019)

Antineutrophil cytoplasmic antibody-positive conversion and microscopic polyangiitis development in patients with idiopathic pulmonary fibrosis
por: Kagiyama, Naho, et al.
Publicado: (2015)

Acute exacerbation of idiopathic pulmonary fibrosis: a 10-year single-centre retrospective study
por: Yamazoe, Masatoshi, et al.
Publicado: (2018)

Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome
por: Jacob, Joseph, et al.
Publicado: (2020)

Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients
por: Proesmans, V. L. J., et al.
Publicado: (2019)

Real-world retrospective observational study exploring the effectiveness and safety of antifibrotics in idiopathic pulmonary fibrosis
por: Wright, William Alexander, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lof8ehkom7e4kva20q71u9tdb4